- Home
- FURY vs VRCA Comparison
FURY vs VRCA Comparison
Compare FURY & VRCA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FURY | VRCA |
|---|---|---|
| Founded | 2008 | 2013 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 97.7M | 87.5M |
| IPO Year | 2011 | 2018 |
Fundamental Metrics
Financial Performance| Metric | FURY | VRCA |
|---|---|---|
| Price | $0.53 | $5.42 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 3 |
| Target Price | $1.70 | ★ $17.00 |
| AVG Volume (30 Days) | ★ 606.4K | 108.5K |
| Earning Date | 03-27-2026 | 03-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $35,577,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $103.06 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 370.22 |
| 52 Week Low | $0.35 | $0.39 |
| 52 Week High | $1.02 | $9.82 |
Technical Indicators
Market Signals| Indicator | FURY | VRCA |
|---|---|---|
| Relative Strength Index (RSI) | 28.47 | 40.73 |
| Support Level | $0.49 | $5.18 |
| Resistance Level | $0.57 | $6.48 |
| Average True Range (ATR) | 0.04 | 0.53 |
| MACD | -0.02 | 0.05 |
| Stochastic Oscillator | 7.01 | 26.60 |
Price Performance
Historical ComparisonAbout FURY Fury Gold Mines Limited
Fury Gold Mines Ltd is a Canadian-focused exploration and development company strategically positioned in three prolific mining regions: James Bay, Quebec; the Golden Triangle, British Columbia; and the Kitikmeot Region Nunavut. Its projects include Eau Claire, Homestake Ridge, Committee Bay, Eleonore South JV, and Gibson MacQuoid.
About VRCA Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.